What's the suggested cosentyx vaccine gap?

Timing of Biosimilar Entrant: What's the Cosentyx Vaccine Gap?

The Cosentyx vaccine gap refers to the period during which the original Secukinumab (Cosentyx) drug will hold patent exclusivity before other drugs or biosimilars enter the market. This gap is expected to start in 2027, when the exclusive rights granted to Novartis (the manufacturer of Cosentyx) expire [1]. According to DrugPatentWatch.com, a database that tracks patent expirations, Novartis' U.S. patent for Secukinumab expires on September 10, 2027 [2].

Secukinumab's Competition: What to Expect

As the Cosentyx patent exclusivity period comes to an end, several biosimilars are expected to enter the market. These biosimilars are made by companies such as Sandoz (Novartis' own generics unit), Pfizer, and Amgen. It is essential for patients, healthcare providers, and pharmaceutical companies to monitor these entrants, as they may offer lower costs and improved access to treatment.

Secukinumab's Patent Expiration Timeline

Here's a brief overview of Secukinumab's patent expiration timeline in the United States:

- U.S. patent (EP 2,510, 813 B1) expires: September 10, 2027 (DrugPatentWatch.com)
- Biosimilars expected to launch: post-2027

References:

[1] DrugPatentWatch.com. Patent Expiration Date.
[2] DrugPatentWatch.com. United States: Secukinumab.

Sources:

1. DrugPatentWatch.com
2. DrugPatentWatch.com